TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Design Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Renee Leck
Design Therapeutics to Participate in Upcoming Investor Conferences

Design Therapeutics plans to initiate patient dosing for DT-818, a potential treatment for Myotonic Dystrophy Type-1, in the first half of 2026. The company has obtained ex-US regulatory clearance and is developing gene-targeted therapies for various genetic diseases.

Insights
GBFH   neutral

The company maintains stability despite the departure of a founding director, with no indication of internal disruption


DSGN   positive

Company is advancing multiple clinical-stage programs, obtaining regulatory clearances, and expanding its genomic medicine research, indicating positive growth and development potential